-transparent.png){kind=logo}
OBJECTIVE The in vitro activity of ertapenem was evaluated in comparison to 21 selected agents against a large collection of recently isolated respiratory tract pathogens including: 180 Streptococcus pneumoniae, 100 Streptococcus pyogenes, 70 Haemophilus influenzae, 70 Moraxella catarrhalis, 100 methicillin-susceptible Staphylococcus aureus and 30 Klebsiella pneumoniae. Additional in vitro tests (time-kill curves with ertapenem alone and in combination with four other agents) for S. pneumoniae were carried out. METHODS MIC determinations and time-kill curves were carried out following the procedures suggested by the NCCLS. RESULTS According to NCCLS susceptibility breakpoints, ertapenem was comparable to the most potent compounds tested for all pathogens studied. Ertapenem was 100% active against penicillin-susceptible and -intermediate S. pneumoniae and against 60% of penicillin-resistant strains. Time-kill tests at 4x MIC confirmed a pronounced bactericidal potency of ertapenem against these organisms. Interactions of ertapenem with several other agents against pneumococci resulted in clear synergic interactions (98.4%). Indifference was extremely rare and antagonism was not observed. All S. pyogenes strains tested were inhibited by ertapenem, irrespective of their macrolide resistance phenotypes. Ertapenem was also fully active against H. influenzae (100% susceptible) and M. catarrhalis (MIC90 0.015-0.03 mg/L) even when capable of synthesizing beta-lactamases. Methicillin-susceptible S. aureus and K. pneumoniae, including extended-spectrum beta-lactamase-producing strains, were 100% susceptible to ertapenem. CONCLUSIONS Our results indicate that ertapenem has a suitable spectrum of activity against organisms encountered in community-acquired bacterial respiratory tract infections.
A Marchese, and
L Gualco, and
A M Schito, and
E A Debbia, and
G C Schito
November 2002,
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
A Marchese, and
L Gualco, and
A M Schito, and
E A Debbia, and
G C Schito
February 1959,
Technical bulletin of the Registry of Medical Technologists. American Society of Clinical Pathologists. Registry of Medical Technologists,
A Marchese, and
L Gualco, and
A M Schito, and
E A Debbia, and
G C Schito
November 1990,
The Journal of antimicrobial chemotherapy,
A Marchese, and
L Gualco, and
A M Schito, and
E A Debbia, and
G C Schito
March 2002,
The Journal of antimicrobial chemotherapy,
A Marchese, and
L Gualco, and
A M Schito, and
E A Debbia, and
G C Schito
October 2003,
Pathologie-biologie,
A Marchese, and
L Gualco, and
A M Schito, and
E A Debbia, and
G C Schito
January 2007,
Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi,
A Marchese, and
L Gualco, and
A M Schito, and
E A Debbia, and
G C Schito
November 2006,
International journal of antimicrobial agents,
A Marchese, and
L Gualco, and
A M Schito, and
E A Debbia, and
G C Schito
January 2006,
The West Indian medical journal,
A Marchese, and
L Gualco, and
A M Schito, and
E A Debbia, and
G C Schito
June 2023,
Antibiotics (Basel, Switzerland),
A Marchese, and
L Gualco, and
A M Schito, and
E A Debbia, and
G C Schito
November 1987,
The Journal of antimicrobial chemotherapy,
